Trial Profile

A Randomized, Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Chinese Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anifrolumab (Primary) ; Anifrolumab (Primary)
Indications Cutaneous lupus erythematosus; Lupus nephritis; Myositis; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors AstraZeneca

24 Mar 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
19 Mar 2025 Status changed from active, no longer recruiting to completed.
18 Dec 2024 Planned End Date changed from 20 Mar 2025 to 13 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com